SystImmune

Focus: SystImmune is a clinical-stage biotechnology company specializing in novel bi-specific, multi-specific antibodies, and antibody-drug conjugates targeting oncology and neurology indications. The company is headquartered in Redmond, WA and operates with a focused pipeline of 26 active programs, most in Phase 1 development.

Oncology Neurology

Profile data last refreshed 6h ago · AI intelligence enriched 1w ago

Open Jobs

54+38 this month

Hot — 47 jobs added in 30d

Net +38 (47 new, 9 removed). Aggressive expansion phase.

Should You Work at SystImmune?

AI assessment

SystImmune is a high-risk, high-learning opportunity best suited for early-career scientists and clinical operatives seeking deep modality expertise in antibody engineering, but not for those prioritizing financial stability or near-term commercial validation.

Why Work Here

Access to cutting-edge modality expertise: the company specializes in bi-specific and multi-specific antibodies plus ADCs, representing high-value technical skill development in a competitive space.

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

26 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GNC-039

Recurrent Glioma

Phase 1

SI-B003

Solid Tumor

Phase 1

BL-M17D1

Breast Cancer Stage III

Help build intelligence for SystImmune

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Significant clinical expansion underway: 49 open roles across Clinical Operations (12), R&D (9), and IT (9) signal active scaling in early-stage program advancement.

Exposure to oncology and neurology breadth: 26 pipeline programs spanning breast cancer, gastric adenocarcinoma, lymphomas, lung cancer, glioma, and hematologic malignancies provide diverse clinical learning.

Watch Out For

Heavy Phase 1 concentration: 15 of 16 active trials are Phase 1, with only 1 Phase 2 and 1 Phase 3 program (Iza-bren), meaning minimal near-term revenue catalysts and higher attrition risk.
Pre-revenue stage with unknown funding: no disclosed revenue, funding amount, employee count, or ticker status creates uncertainty around cash runway, financial stability, and long-term viability.

Generated by Claude from SystImmune's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Clinical Trials (1)

NCT06714617Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Phase 1

BL-M14D1

Small Cell Lung Cancer Metastatic or Locally Advanced

Phase 1

Clinical Trials (2)

NCT07625644Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

Phase 3

NCT07080242Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Phase 1

BL-B01D1